Researchers will compare transdermal estradiol group to control group, and resistance training groups and non-training control groups. conditions: Prostate Cancer studyType: INTERVENTIONAL phases: PHASE2 allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Participants are randomized in a 1:1 fashion to receive transdermal estradiol and androgen deprivation or solely androgen deprivation therapy. In addition subgroup of participants are randomized in a 1:1 fashion to perform resistance training or to be allocated in non-training control group. primaryPurpose: TREATMENT masking: NONE count: 310 type: ESTIMATED name: Transdermal estrogen name: Active Comparator: Androgen deprivation therapy name: Resistance training measure: The efficacy of transdermal estradiol in mitigating the deterioration of EPIC-26 (The Expanded Prostate Cancer Index Composite) sexual function domain scores caused by androgen deprivation therapy. measure: The occurrence of androgen deprivation therapy induced adverse effects. measure: Number of participants with transdermal estradiol-related adverse events as assessed by CTCAE (Common Terminology Criteria for Adverse Events). measure: Impact of transdermal estradiol with or without 6-month supervised resistance training on one repetition maximum tests of both the leg press and barbell biceps curl, and maximal hand grip strength assessed with a dynamometer. measure: Impact of transdermal estradiol with or without 6-month supervised resistance training on explosive strength of the leg extensors assessed with a countermovement jump (CMJ). measure: Impact of transdermal estradiol with or without 6-month supervised resistance training on 6-minute walk (functional capacity). measure: Impact of transdermal estradiol with or without 6-month supervised resistance training on loaded 10-stair climb test (functional capacity). measure: Impact of transdermal estradiol with or without 6-month supervised resistance training on body composition. measure: Impact of transdermal estradiol with or without 6-month supervised resistance training on bone mineral density. measure: Impact of transdermal estradiol with or without 6-month supervised resistance training on mid-thigh muscle mass. measure: Impact of transdermal estradiol with or without 6-month supervised resistance training on mid-thigh fat mass. measure: Impact of transdermal estradiol with or without 6-month supervised resistance training on hormone (testosterone and estradiol) levels, and cancer (PSA) status. measure: Impact of transdermal estradiol with or without 6-month supervised resistance training on concentration of PVK, IL-6, TNF-α, AFOS, Alat, Krea, Cholesterol, LDL-C, HDL-C, and triglycerides). measure: Impact of transdermal estradiol with or without 6-month supervised resistance training on type I and II myofibers' cross-sectional area, myonuclei, myonuclear domain, the satellite cell count, androgen receptor and myostatin content measure: Impact of transdermal estradiol with or without 6-month supervised resistance training on muscle cellular function (e.g., HSP70, alpha B-crystallin, HSP60, cytochrome c oxidase subunit IV proteins) measure: Number of participants with resistance training induced adverse events. measure: The World Health Organization Quality of Life Brief Version (WHOQOL-BREF). measure: The Patient Health Questionnaire score (PHQ-9) overall and subdomain score. sex: MALE minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False